Clinical Trials
2 trialsNCT03592264 2024-10-15
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Terminated
NCT02423343 2021-09-09
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
Phase 1/2 Completed